Cervarix
human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed)
Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed)
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
This medicine has been prescribed for you only. Do not pass it on to others.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
What Cervarix is and what it is used for
What you need to know before you receive Cervarix
How Cervarix is given
Possible side effects
How to store Cervarix
Contents of the pack and other information
Cervarix is a vaccine intended to protect from the age of 9 years against the diseases caused by infection with Human Papillomaviruses (HPV).
These diseases include:
cervical cancer (cancer of the cervix i.e. lower part of the uterus or womb) and anal cancer,
precancerous cervical, vulvar, vaginal and anal lesions (changes in genital or anal cells that have a risk of turning into cancer).
The Human Papillomavirus (HPV) types contained in the vaccine (HPV types 16 and 18) are responsible for approximately 70% of cervical cancers, 90% of anal cancers, 70% of HPV-related pre- cancerous lesions of the vulva and vagina and 78% of HPV-related pre-cancerous lesions of the anus. Other HPV types can also cause ano-genital cancers. Cervarix does not protect against all HPV types.
When a female or a male individual is vaccinated with Cervarix, the immune system (the body’s natural defence system) will make antibodies against HPV types 16 and 18.
Cervarix is not infectious and so, it cannot cause HPV related diseases.
Cervarix is not used to treat HPV related diseases already present at the time of vaccination. Cervarix should be used in accordance with official guidelines.
if you are allergic to any of the active substances or any of the other ingredients of this vaccine (listed in section 6). Signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue.
Talk to your doctor or pharmacist before you are given Cervarix
if you have a bleeding problem or bruise easily.
if you have any disease which reduces your resistance to infection such as HIV infection.
if you have a severe infection with a high temperature. It might be necessary to postpone the vaccination until recovery. A minor infection such as a cold should not be a problem, but talk to the doctor first.
Fainting can occur (mostly in adolescents) following, or even before, any needle injection. Therefore tell the doctor or nurse if you or your child fainted with a previous injection.
As with all vaccines, Cervarix may not fully protect all people who are vaccinated.
Cervarix does not protect people from diseases caused by infection with HPV types 16 or 18 if they are already infected with Human Papillomavirus type 16 or 18 at the time of vaccination.
Although vaccination may protect you against cervical cancer, it is not a substitute for regular cervical screening. You should continue to follow your doctor’s advice on cervical smear/Pap test (test to screen for changes in cells of the cervix caused by an HPV infection) and preventative and protective measures.
As Cervarix will not protect against all types of Human Papillomavirus, appropriate precautions against exposure to HPV and sexually transmitted diseases should continue to be used.
Cervarix will not protect against other diseases that are not caused by Human Papillomavirus.
Cervarix can be given with a combined booster vaccine containing diphtheria (d), tetanus (T) and pertussis [acellular] (pa) with or without inactivated poliomyelitis (IPV), (dTpa, dTpa -IPV vaccines), with a combined hepatitis A and hepatitis B vaccine (Twinrix) or a hepatitis B vaccine (Engerix B), or with a meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (MenACWY-TT), at a separate injection site (another part of your body, e.g. the other arm) during the same visit.
Cervarix may not have an optimal effect if used with medicines that suppress the immune system.
In clinical trials, oral contraceptives (e.g. the pill) did not reduce the protection obtained by Cervarix. Tell your doctor if you are taking, have recently taken, might take any other medicines, or have
recently received any other vaccine.
If you are pregnant, if pregnancy occurs during the course of vaccination or if you are trying to become pregnant it is recommended to postpone or interrupt vaccination until after completion of the pregnancy.
If you are pregnant or breast-feeding, think that you may be pregnant or are planning to have a baby, ask your doctor for advice before you are given this vaccine.
Cervarix is not likely to affect your ability to drive or use machines. However, do not drive or use any
machines if you are feeling unwell.
This vaccine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially “sodium- free”.
The doctor or nurse will give Cervarix as an injection into the muscle of the upper arm.
Cervarix is intended for use from 9 years of age onwards.
The total number of injections you will receive depends on your age at the time of the first injection. If you are between 9 and 14 years old
You will receive 2 injections:
First injection: at chosen date
Second injection: given between 5 and 13 months after first injection If you are 15 years old or above
You will receive 3 injections:
First injection: at chosen date
Second injection: 1 month after first injection
Third injection: 6 months after first injection
If necessary, the vaccination schedule can be more flexible. Please speak to your doctor for more information.
When Cervarix is given for the first dose, it is recommended that Cervarix (and not another vaccine against HPV) be given for the complete vaccination course.
Cervarix is not recommended for use below 9 years of age. The vaccine should never be given into a vein.
It is important that you follow the instructions of your doctor or nurse regarding return visits. If you forget to go back to your doctor at the scheduled time, ask your doctor for advice.
If you do not finish the complete vaccination course (two or three injections depending on your age at vaccination), you may not get the best response and protection from the vaccination.
Like all medicines, this vaccine can cause side effects, although not everybody gets them. Side effects that occurred during clinical trials with Cervarix were as follows:
Very common (side effects which may occur in more than 1 per 10 doses of vaccine):
pain or discomfort at the injection site
redness or swelling at the injection site
headache
aching muscles, muscle tenderness or weakness (not caused by exercise)
tiredness
Common (side effects which may occur in less than 1 per 10 but more than 1 per 100 doses of vaccine):
gastrointestinal symptoms including nausea, vomiting, diarrhoea and abdominal pain
itching, red skin rash, hives (urticaria)
joint pain
fever (≥38°C)
Uncommon (side effects which may occur in less than 1 per 100 but more than 1 per 1,000 doses of vaccine):
upper respiratory tract infection (infection of the nose, throat or trachea)
dizziness
other injection site reactions such as hard lump, tingling or numbness. Side effects that have been reported during marketed use of Cervarix include:
allergic reactions. These can be recognised by: itchy rash of the hands and feet,
swelling of the eyes and face,
difficulty in breathing or swallowing,
sudden drop in blood pressure and loss of consciousness.
These reactions will usually occur before leaving the doctor’s surgery. However, if your child gets any of these symptoms you should contact a doctor urgently.
swollen glands in the neck, armpit or groin
fainting sometimes accompanied by shaking or stiffness.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this vaccine out of the sight and reach of children.
Do not use this vaccine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.
Store in a refrigerator (2°C – 8°C). Do not freeze.
Store in the original package in order to protect from light.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
The active substances are:
Human Papillomavirus1 type 16 L1 protein2,3,4 20 micrograms
Human Papillomavirus1 type 18 L1 protein2,3,4 20 micrograms
1Human Papillomavirus = HPV
2adjuvanted by AS04 containing:
3-O-desacyl-4’- monophosphoryl lipid A (MPL)3 50 micrograms
3adsorbed on aluminium hydroxide, hydrated (Al(OH)3) 0.5 milligrams Al3+ in total
4L1 protein in the form of non-infectious virus-like particles (VLPs) produced by recombinant DNA technology using a Baculovirus expression system which uses Hi-5 Rix4446 cells derived from the insect Trichoplusia ni.
The other ingredients are sodium chloride (NaCl), sodium dihydrogen phosphate dihydrate (NaH2PO4.2 H2O) and water for injections.
Suspension for injection.
Cervarix is a turbid white suspension.
Cervarix is available in 1 dose vials (0.5 ml) in packs of 1, 10 and 100. Not all pack sizes may be marketed.
GlaxoSmithKline Biologicals s.a. Rue de l'Institut 89
B-1330 Rixensart, Belgium
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
GlaxoSmithKline Biologicals SA Tel: +370 80000334
GlaxoSmithKline Biologicals SA
Тел. +359 80018205
GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00
GlaxoSmithKline Biologicals SA Tel: +356 80065004
GlaxoSmithKline GmbH & Co. KG Tel: + 49 (0)89 360448701
GlaxoSmithKline Biologicals SA
Tel: +372 8002640
GlaxoSmithKline Μονοπρόσωπη A.E.B.E Tηλ: + 30 210 68 82 100
GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0
GSK Services Sp. z o.o. Tel.: + 48 (22) 576 9000
Laboratoire GlaxoSmithKline Tél: + 33 (0) 1 39 17 84 44
GlaxoSmithKline Biologicals SA Tel.: +385 800787089
GlaxoSmithKline - Produtos Farmacêuticos, Lda.
Tel: + 351 21 412 95 00
GlaxoSmithKline Biologicals SA Tel: +40 800672524
GlaxoSmithKline (Ireland) Ltd Tel: + 353 (0)1 495 5000
GlaxoSmithKline Biologicals SA Tel: +386 80688869
Vistor hf.
Sími: +354 535 7000
GlaxoSmithKline S.p.A.
Tel:+ 39 (0)45 7741 111
GlaxoSmithKline Biologicals SA
Τηλ: +357 80070017
GlaxoSmithKline Biologicals SA Tel: +371 80205045
GlaxoSmithKline Biologicals SA Tel: +44(0)800 221441
-------------------------------------------------------------------------------------------------------------------------
The following information is intended for healthcare professionals only:
Cervarix should be administered as soon as possible after being removed from the refrigerator. However, stability has been demonstrated when stored outside the
refrigerator for up to 3 days at temperatures between 8°C and 25°C or for up to 1 day at temperatures between 25°C and 37°C. If not used at the end of this period the vaccine should be discarded.
A fine white deposit with a clear colourless supernatant may be observed upon storage of the vial. This does not constitute a sign of deterioration.
The content of the vial should be inspected visually both before and after shaking for any foreign particulate matter and/or abnormal physical appearance prior to administration.
In the event of either being observed, discard the vaccine. The vaccine should be well shaken before use.
Any unused medicinal product or waste material should be disposed of in accordance with local
requirements.